Postersession 2
Blood Components | Blood Donation | Blood Safety | Hemostaseology

Programm

• 16:30 – 16:33 2 Min. 1 Min.

  • ePoster
  • PS-2-1

  In-vitro quality of platelet concentrates, x-ray-irradiated, at the beginning or end of storage

  • Susann Zilkenat (Springe/ DE)

   Blood Components
• 16:33 – 16:36 2 Min. 1 Min.

  • ePoster
  • PS-2-2

  In vitro quality of pediatric and standard units of packed red blood cells after x-ray irradiation

  • Dr. Ute Gravemann (Springe/ DE)

   Blood Components
• 16:36 – 16:39 2 Min. 1 Min.

  • ePoster
  • PS-2-3

  Optimization of the pooling time during the preparation of platelet concentrates in octopus configuration with a new sterile multiple connection device

  • Massimo Benzoni (Langen/ DE)

   Blood Components
• 16:39 – 16:42 2 Min. 1 Min.

  • ePoster
  • PS-2-4

  Validation of a pneumatic tube system for transport of blood products (EC, PC, TP)

  • Dip.Ing. (FH) Frauke Dormann (Regensburg/ DE)
  • Dr. Viola Hähnel (Regensburg/ DE)

   Blood Components
• 16:42 – 16:45 2 Min. 1 Min.

  • ePoster
  • PS-2-5

  Ensuring the stability of serum eye drops

  • Claudia Loimayr (Linz/ AT)

   Blood Components
• 16:45 – 16:48 2 Min. 1 Min.

  • ePoster
  • PS-2-6

  Over 6 years experience in allogenic serum eye drop manufacturing

  • Dr. Aylin Pamuk (Köln/ DE)

   Blood Components
• 16:48 – 16:51 2 Min. 1 Min.

  • ePoster
  • PS-2-7

  Investigation of a Perfluorodecalin nanoemulsion as an artificial oxygen carrier in whole blood and 3D-printed blood vessels

  • Jan-Eric Sydow (Essen/ DE)

   Blood Components
• 16:51 – 16:54 2 Min. 1 Min.

  • ePoster
  • PS-2-8

  Production of metabolically improved Red Cell Concentrates under an new GMP Protocol under Hypoxia

  • Bianca Grahl (Leipzig/ DE)

   Blood Components
• 16:54 – 16:57 2 Min. 1 Min.

  • ePoster
  • PS-2-9

  Implementation of a perfluorocarbon-based artificial oxygen carrier in normothermic porcine heart perfusion

  • Jacqueline Hausherr (Essen/ DE)

   Blood Components
• 16:57 – 17:00 2 Min. 1 Min.

  • ePoster
  • PS-2-10

  More than 6 years experience with the collection of granulocytes using modified fluid gelatin 4%

  • Dr. Morad Mohrez (Regensburg/ DE)

   Blood Components
• 17:00 – 17:03 2 Min. 1 Min.

  • ePoster
  • PS-2-11

  Purified granulocyte concentrates from buffy coats with extended storage time

  • Dr. Jens Altrichter (Rostock/ DE)

   Blood Components
• 17:03 – 17:06 2 Min. 1 Min.

  • ePoster
  • PS-2-12

  Assessment of purified granulocyte preparations in multiple environmental settings

  • Dr. Gerd Klinkmann (Rostock/ DE)
  • Dr. Jens Altrichter (Rostock/ DE)

   Blood Components
• 17:06 – 17:09 2 Min. 1 Min.

  • ePoster
  • PS-2-13

  Demographic changes of first-time donors over the last 20 years in Upper Austria

  • MSc Susanne Süßner (Linz/ AT)

   Blood Donation
• 17:09 – 17:12 2 Min. 1 Min.

  • ePoster
  • PS-2-14

  Influences on blood donor return rate and donation interval

  • MSc Susanne Süßner (Linz/ AT)

   Blood Donation
• 17:12 – 17:15 2 Min. 1 Min.

  • ePoster
  • PS-2-15

  Case report: Blood donation with a contraceptive stick on one arm

  • Karla Beatriz Hernandez Juarez (Köln/ DE)

   Blood Donation
• 17:15 – 17:18 2 Min. 1 Min.

  • ePoster
  • PS-2-16

  Impact of positive testing for Hepatitis E virus on donor return

  • Prof. Dr. Tanja Vollmer (Bad Oeynhausen/ DE)

   Blood Donation
• 17:18 – 17:21 2 Min. 1 Min.

  • ePoster
  • PS-2-17

  "Disposal Approach" to meet the challenges in provision of high volume donations for diagnostic industry in Europe

  • Dr. Dirk Lassner (Hennigsdorf/ DE)

   Blood Donation
• 17:21 – 17:24 2 Min. 1 Min.

  • ePoster
  • PS-2-18

  2 Years of experience in HEV Screening of plasma donors

  • Viktoria Dienst (Leipzig/ DE)

   Blood Safety
• 17:24 – 17:27 2 Min. 1 Min.

  • ePoster
  • PS-2-19

  Impact of hepatitis E notification on donor return

  • PD Dr. Franz F. Wagner (Springe/ DE)

   Blood Safety
• 17:27 – 17:30 2 Min. 1 Min.

  • ePoster
  • PS-2-20

  Evaluation of a new PCR-based CMV assay for blood donor screening

  • Dr. Marijke Weber-Schehl (Wiesentheid/ DE)

   Blood Safety
• 17:30 – 17:33 2 Min. 1 Min.

  • ePoster
  • PS-2-21

  Routine blood donor screening on a new NAT platform

  • Dr. Marijke Weber-Schehl (Wiesentheid/ DE)

   Blood Safety
• 17:33 – 17:36 2 Min. 1 Min.

  • ePoster
  • PS-2-22

  Reduction in the initial reactive rate by a new HBsAg assay version

  • Prof. Dr. Jens Dreier (Bad Oeynhausen/ DE)

   Blood Safety
• 17:36 – 17:39 2 Min. 1 Min.

  • ePoster
  • PS-2-23

  Health-related quality of life in Iranian adult men with severe hemophilia

  • Ehsan Shahverdi (Osnabrück/ DE)

   Hemostaseology
• 17:39 – 17:42 2 Min. 1 Min.

  • ePoster
  • PS-2-24

  Two novel VWF gene mutations associated with von Willebrand Disease type 1

  • Prof. Dr. Robert Zimmermann (Erlangen/ DE)

   Hemostaseology
• 17:42 – 17:45 2 Min. 1 Min.

  • ePoster
  • PS-2-25

  A SERPINE1 gene mutation possibly associated with intraoperative bleeding

  • Prof. Dr. Robert Zimmermann (Erlangen/ DE)

   Hemostaseology
• 17:45 – 17:48 2 Min. 1 Min.

  • ePoster
  • PS-2-26

  Structural characterization of B domain and full-length of coagulation factor VIII

  • Samhitha Urs Ramaraje Urs (Bonn/ DE)

   Hemostaseology
• 17:48 – 17:51 2 Min. 1 Min.

  • ePoster
  • PS-2-27

  SpikeIn studies for the diagnosis of coagulation disorders using Thrombelastography

  • Leah Heuer (Tübingen/ DE)

   Hemostaseology
• 17:51 – 17:54 2 Min. 1 Min.

  • ePoster
  • PS-2-28

  Platelet-activating factor promotes activation of neutrophil granulocytes in conjunction with the formation of platelet-neutrophil complexes

  • PD Dr. David Alexander Christian Messerer (Ulm/ DE)

   Hemostaseology
• 17:54 – 17:57 2 Min. 1 Min.

  • ePoster
  • PS-2-29

  The impact of different platelet subpopulations on platelet-neutrophil interaction

  • Johannes Hirsch (Tübingen/ DE)

   Hemostaseology